Minireviews
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Virol. Mar 25, 2024; 13(1): 88487
Published online Mar 25, 2024. doi: 10.5501/wjv.v13.i1.88487
Hepatitis B virus reactivation in patients treated with monoclonal antibodies
Silvia De Pauli, Martina Grando, Giovanni Miotti, Marco Zeppieri
Silvia De Pauli, Martina Grando, Department of Internal Medicine, Azienda Sanitaria Friuli Occidentale, San Vito al Tagliamento, Pordenone 33170, Italy
Giovanni Miotti, Department of Plastic Surgery, University Hospital of Udine, Udine 33100, Italy
Marco Zeppieri, Department of Ophthalmology, University Hospital of Udine, Udine 33100, Italy
Co-first authors: Silvia De Pauli and Martina Grando.
Author contributions: Grando M, De Pauli S and Zeppieri M wrote the outline; Grando M and De Pauli S performed the research and wrote the manuscript together as co-authors; Grando M, De Pauli S, Miotti G, and Zeppieri M assisted in the writing of the paper; Zeppieri M was responsible for the conception and design of the study and completed the English and scientific editing; Grando M, De Pauli S, Miotti G and Zeppieri M assisted in the editing and making critical revisions to the manuscript. Although authors are from different areas of specialization, all authors provided general information and details regarding Hepatitis B virus reactivation based on the literature review. Each author participated in the research and writing of the paper, even if not directly pertinent to the area of study, considering the multidisciplinary approach in managing these patients. All authors provided the final approval of the article.
Conflict-of-interest statement: The authors declare having no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Marco Zeppieri, BSc, MD, PhD, Doctor, Department of Ophthalmology, University Hospital of Udine, p.le S. Maria della Misericordia 15, Udine 33100, Italy. markzeppieri@hotmail.com
Received: September 26, 2023
Peer-review started: September 26, 2023
First decision: November 23, 2023
Revised: November 23, 2023
Accepted: December 19, 2023
Article in press: December 19, 2023
Published online: March 25, 2024
Processing time: 167 Days and 2.3 Hours
Core Tip

Core Tip: Reactivation of hepatitis B (HBV) induces a rapid and acute increase in viral replication in a patient with chronic HBV infection or prior HBV exposure. There is also an increased risk of HBV reactivation in patients treated with monoclonal antibodies. Organ damage can be due to various mechanisms and risk factors that activate the cascade of inflammatory responses, such as direct infection. It is of clinical importance to diagnose, manage, and treat individuals, especially those at risk. Patient outcomes, success of therapy, prevention of complications, and management of existing comorbidities depend on the correct multidisciplinary management in patients at risk.